Ribonuclease >100 U/mg Source : Bovine pancreas

Added to your cart

Ribonuclease >100 U/mg Source : Bovine pancreas

Cart subtotal: £0.00

View cart (0) Checkout

#SKU 181515R02

Get in touch to purchase this product

Contact our team of experts to discuss your requirements

Contact our expert team

Product Details

Ribonuclease (RNase) is classified as an endonuclease, which specifically cleaves phosphodiester bonds at the 3’-end of pyrimidine nucleosides and at the 5’-ribose of a nucleotide, ribonucleic acid (RNA). Ribonuclease can be used in the following applications: + In isolation of DNA for RNA-free DNA, especially plasmid DNA + Structural studies of RNA + The depolymerisation of viscous biological suspensions, rendering RNA-free solutions
181515R02

More information

Attributes

Description

  • Shipping Information
  • Ambient Shipping
  • Abbreviations
  • Rnase
  • Specification
  • Salmonella: 0 Pseudomonas aeruginosa: 0 Staphyloccus aureus: 0 E. coli: 0 Total Aerobic Microbial Count: ≤1000 Total Combined Yeast & Mould Count: Record Moisture: ≤5%
  • Lead Time
  • 12 weeks
  • Storage
  • -20
  • Presentation Matrix
  • White, chromatographically purified salt-free, freeze-dried powder
  • Source
  • Bovine pancreas
  • Activity
  • ≥100 U/mg material
  • EC Number
  • 3.1.27.5

Technical Documents

181515R02 Product Specification (82.04KB)

Product Specification (82.04KB)

Sorry, no results found.

Enter the full lot number and hit enter.

BBI Solutions Brands

diarect.png

The acquisition of DIARECT in June 2020 and their world leading recombinant autoimmune antigen capability immediately enhances BBI’s portfolio and position as a ‘complete’ immunoassay reagent supplier. This further enhances BBI’s position as the world’s largest diagnostics components company with a market leading antigen portfolio.

mbs.png

Maine Biotechnology Services brings 27 years of knowledge, experience, process development, and project management to our customers to ensure the best possible antibodies for any application. As antibody development goals in the biotechnology and pharmaceutical industry have evolved the acquisition of MBS will help BBI further meet and exceed our customers needs.

Newsletter

Signup for our newsletter to receive the latest BBI Solutions updates and special offers in your inbox